News about Market

Boehringer and Simcere Partner on Dual-Target IBD Antibody

Boehringer Ingelheim has signed a licence and collaboration deal with Simcere to develop a novel TL1A/IL23p19 bispecific antibody for inflammatory bowel disease, gaining global rights outside greater China, with Simcere eligible for up to €1.058 billion in payments.

Market | 29/01/2026 | By News Bureau |  128

Davaindia Launches 77 New Stores Nationwide to Mark India's 77th Republic Day

The expansion by Zota Healthcare’s generic pharmacy chain strengthens access to affordable medicines across metros and Tier II and III cities under its “Har Ghar Ki Pharmacy” vision.

Market | 28/01/2026 | By News Bureau |  343

India's OTC Market Projected to Reach INR 98,000 Crore by 2030, EY Report Says

A new report by EY projects that India’s over-the-counter (OTC) drug market is expected to nearly double by 2030, reaching INR 98,000 crore, up from around INR 47,000 crore in 2024, growing at a compound annual growth rate of about 13 per cent.

Market | 28/01/2026 | By Darshana |  291

Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal

According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.

Market | 28/01/2026 | By News Bureau |  157

Merck Ends Acquisition Talks With Revolution Medicines

Merck has ended discussions to acquire cancer drug developer Revolution Medicines after the two sides failed to agree on valuation, according to reports. The talks, which had been ongoing for several weeks, were discontinued as differences over pricing could not be resolved.

Market | 27/01/2026 | By Darshana |  139

Mair Therapeutics and Radboud University Partner to Advance Parkinson's Therapy

Mair Therapeutics has entered into a scientific collaboration with Radboud University to advance the development of TMEM175 agonists for Parkinson’s disease, with Dr Marijn Kuijpers’ laboratory at the Donders Centre for Neuroscience evaluating a portfolio of TMEM175-targeting compounds developed by the company.

Market | 27/01/2026 | By News Bureau |  197

Syngene International Q3 FY26 Revenue Slips Three Percent; Profit Impacted by One-Off Gratuity Provision

Syngene International reported a muted financial performance for the third quarter of FY26, with consolidated revenue declining three percent year on year to INR nine hundred thirty two crore, compared with INR nine hundred sixty two crore in the same quarter last year. Profit after tax, before exceptional items, stood at INR seventy three crore.

Market | 23/01/2026 | By Darshana |  549

Dr Reddy's Q3 FY26 Net Profit Falls Fourteen Percent Despite Revenue Growth

Dr Reddy’s Laboratories reported consolidated revenue of INR eight thousand seven hundred twenty seven crore in the third quarter of financial year twenty six, registering year on year growth.

Market | 23/01/2026 | By Darshana |  328

Zydus Launches World's First Nivolumab Biosimilar 'Tishtha' in India

Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the immunotherapy drug nivolumab, in India, aimed at expanding access to advanced cancer care by offering the treatment at nearly one-fourth the cost of the reference product for patients with multiple cancer types.

Market | 23/01/2026 | By News Bureau |  756

G Square Backs Serres in Majority Acquisition to Drive Global Growth

G Square, a European healthcare-focused private equity firm investing in high-growth mid-market companies, has signed an agreement to acquire a majority stake in Serres, a global leader in sustainable surgical fluid management solutions.

Market | 21/01/2026 | By Darshana |  275